Advertisement Pharmaceutical Business review - Page 5 of 5211 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
May 3, 2024

Latus Bio secures $54m for CNS gene therapy development

Latus Bio, a biotechnology company specialising in new gene therapy candidates for central nervous system (CNS) disorders, has announced its launch alongside an initial $54m Series A financing.

Continue
Latus's capsid variants have shown high gene expression in targeted CNS locations. Credit: Arek Socha from Pixabay.
May 2, 2024

Celltrion secures new public tenders for two biosimilars in Peru

May 1, 2024

Scenic Biotech, Bristol Myers Squibb to develop new drug targets

Through the new partnership, Scenic Biotech aims to reinforce its focus on the application of its Cell-Seq technology to identify modifier genes. Credit: © Scenic Biotech.

Contracts

December 14, 2022

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Micrograph of psoriasis vulgaris. Credit: Jenny Giang, Marc A. J. Seelen, Martijn B. A. van Doorn, Robert Rissmann,Errol P. Prens and Jeffrey Damman/ commons.wikimedia.org.

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Harbour BioMed, Moderna partner on immunotherapies development

Kite, Refuge sign license deal for gene expression platform for blood cancers

Deals

Deals April 18, 2024

Biocon signs licensing and supply deal for diabetes drug in Brazil

Pharmaceutical Business Review

Q32 Bio concludes merger deal with Homology Medicines

Zuellig Pharma acquires Cialis and Alimta brands from Lilly

Kindeva Drug Delivery acquires Summit Biosciences

Popular

  1. Genmab and Pfizer’s TIVDAK sBLA secures full FDA approval
  2. FDA approves Ractigen Therapeutics’ RAG-01 IND for bladder cancer
  3. PRISM, ONO to co-create development candidate for oncology target
  4. US FDA accepts sBLA for GSK’s Jemperli for broader endometrial cancer use
  5. OSR Holdings, SillaJen sign MoU to pursue drug development

PRESS RELEASES

Gerresheimer Performance Levels Simplify Choice of Optimum Solution
Gerresheimer Performance Levels Simplify Choice of Optimum Solution
Sofgen Pharmaceuticals to Exhibit at CPhI North America 2024
Sofgen Pharmaceuticals to Exhibit at CPhI North America 2024
Molnar Institute at Analytica 2024 – 9-12 April in Munich, Germany
Molnar Institute at Analytica 2024 – 9-12 April in Munich, Germany
Gerresheimer Decisively Continues on Profitable Growth Course in Financial Year 2023
Gerresheimer Decisively Continues on Profitable Growth Course in Financial Year 2023
Butterworth at Making Pharmaceuticals 2024 – 23-24 April in Coventry, UK
Butterworth at Making Pharmaceuticals 2024 – 23-24 April in Coventry, UK

Suppliers

Whitepapers

Wound Care – Selecting the Right Antiseptic for Your Formulation
Wound Care – Selecting the Right Antiseptic for Your Formulation
Topicals – Selecting the Right Antiseptic for Your Formulation
Topicals – Selecting the Right Antiseptic for Your Formulation
Oral Formulations – Selecting the Right Antiseptic for Your Formulation
Oral Formulations – Selecting the Right Antiseptic for Your Formulation